

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
At scoping consultation, consultees raised that the risk of multiple myeloma is higher in men than in women, in older people, and in people of African and Caribbean ethnic backgrounds. The committee considered that its recommendation applies equally, regardless of sex, age or ethnic background. It concluded that these differences in prevalence did not itself represent an equality issue in this evaluation
2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No
3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
The committee's considerations of the equality issues are discussed in section 3.15 of the FDG.

Approved by Associate Director (name): ...Dr Emily Crowe...

Date: 01/03/2024